Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

UCB : UCB’s Executive Committee with two new members

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/25/2011 | 07:15am CEST

• Greg Duncan, Executive Vice President, President of North American Operations

• Jean-Christophe Tellier, MD, Executive Vice President, President of European Operations

Vers la version en français

Naar de nederlandstalige versie

BRUSSELS, 25 May 07:00 (CET) - regulated information - With UCB set to enter its growth phase in 2012 and building on major advances in its late-stage pipeline, UCB announced today that two new members will join the company’s Executive Committee as of July 1, 2011.

The two new members are the heads of the US and European commercial operations, respectively Greg Duncan, currently Senior Vice President and President of UCB’s North American Operations, and Jean-Christophe Tellier, joining UCB from Ipsen.

These additions will allow Mark McDade, UCB’s EVP Global Operations and Chief Operating Officer to focus on UCB’s future growth markets outside the US and Europe, while driving UCB’s commercial growth strategy across all geographies. Mark will also continue to lead Business Development and maintains his global leadership of the company’s Marketing, Access and Medical Affairs functions, preparing the launch and commercialization of the next generation of medicines from UCB’s promising late-stage pipeline, such as brivaracetam in epilepsy, epratuzumab in Lupus and Sclerostin antibody in post-menopausal osteoporosis and fracture healing.

Greg Duncan joined UCB in 2007 to lead UCB’s European Operations. He then became President of European and Emerging Market Operations until 2009 when he was appointed President of UCB’s North American operations. Greg has a degree in Economics from the State University of New York, Albany, and a MBA in Marketing and Management from the Emory University in Atlanta. He started his career in 1989, within Pfizer, where he had spent 17 years holding various managerial positions. His last position within Pfizer was as President Latin America.

Jean-Christophe Tellier is joining UCB from Ipsen where he was President & General Manager Ipsen US. His role at Ipsen was to strengthen Ipsen’s specialty care business in North America, in the areas of endocrinology and neurology. Prior to joining Ipsen in May 2009, he was Executive Vice President and Chief Commercial Officer at MacroGenics Inc, a Maryland-based biotechnology company. Jean-Christophe Tellier spent the largest part of his career at Novartis (Ciba) where he held several commercial operations roles in France, Belgium and Switzerland. Jean-Christophe Tellier is a physician specialized in rheumatology (University of Paris V, France).

Detailed biographies of the members of the Executive Committee can be found on UCB’s website.

For further Information:

Antje Witte, Investor Relations, UCB

T +32.2.559.9414,

Michael Tuck-Sherman, Investor Relations, UCB

T +32.2.559.9712, Michael.tuck-sherman@ucb.comantje.witte@ucb.com

About UCB

UCB, Brussels, Belgium () is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 9000 people in over 40 countries, UCB produced revenue of EUR 3.22 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

Forward-looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.

www.ucb.com

UCB Media Room

e: UCB.MediaRoom@ucb.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on UCB
08/03 UCB : Reports Summarize Parkinson's Disease Study Results from UCB S.A. (U18666A..
08/03 UCB : S.A. - Transparency notification The Capital Group Companies
08/03 UCB : Transparency Notification the Capital Group Companies
07/27 UCB : Amgen And UCB Provide Update On Regulatory Status Of EVENITY romosozumab I..
07/27 UCB : with a strong first half year 2017 – giving rise …
07/25 UCB : and Dermira Announce U.S. and EU Regulatory Submissions …
07/24 UCB : anti-epileptic drug VIMPAT® (lacosamide) receives EU CHMP …
07/21 UCB : Bimekizumab Demonstrates Skin Clearance in Phase 2b Psoriasis Study with &..
07/17 UCB : and Amgen Provide Update on Regulatory Status of EVENITY …
07/06 UCB : Study Findings on Clinical Pharmacology Are Outlined in Reports from UCB S..
More news
News from SeekingAlpha
07/31 UCB's (UCBJF) CEO Jean Tellier on Q2 2017 Results - Earnings Call Transcript
07/17 FDA rejects Amgen's marketing application for osteoporosis candidate romosozu..
05/22 Amgen's and UCB's romosozumab successful in late-stage osteoporosis study but..
03/21 UCB Needs Clinical Success To Drive Upside
02/24 UCB S.A. 2016 Q4 - Results - Earnings Call Slides
Financials (€)
Sales 2017 4 334 M
EBIT 2017 950 M
Net income 2017 604 M
Debt 2017 565 M
Yield 2017 2,07%
P/E ratio 2017 17,25
P/E ratio 2018 14,78
EV / Sales 2017 2,73x
EV / Sales 2018 2,50x
Capitalization 11 272 M
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 66,1 €
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB-4.86%13 278
JOHNSON & JOHNSON15.77%357 992
NOVARTIS10.12%219 731
ROCHE HOLDING LTD.5.33%217 452
PFIZER2.71%198 782
MERCK AND COMPANY6.51%170 460